Generally, the molecules used to predict the prognosis and therapeutic responses, such as the carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), exhibit relatively low sensitivity and specificity; therefore, there is a necessity for molecular signatures to identify patients in the early stages of CRC (4). Here, CEACAM5 is linked to colorectal carcinoma.